Business Context and Reporting Period
The filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018. This conflicts with the request metadata identifying Bio Green Med Solution, Inc.; confirm the intended issuer. Cyclacel is a clinical-stage biopharmaceutical company with no reported revenue, focused on cancer drug development, including CYC065, sapacitabine, and seliciclib.
Financial Results and Liquidity
Amounts below are in millions of dollars except per-share data. The company reported no revenue in either comparable period.
| Metric | Q2 2018 | Q2 2017 | First half 2018 | First half 2017 |
|---|---|---|---|---|
| Research and development expense | $1.182 | $1.222 | $1.980 | $2.534 |
| General and administrative expense | $1.283 | $1.267 | $2.647 | $2.648 |
| Operating loss | $(2.465) | $(2.489) | $(4.627) | $(5.182) |
| Net loss | $(1.852) | $(2.187) | $(3.201) | $(3.742) |
| Net loss applicable to common shareholders | $(1.902) | $(2.237) | $(3.302) | $(3.842) |
| Basic and diluted loss per share | $(0.16) | $(0.50) | $(0.28) | $(0.88) |
At June 30, 2018, cash and cash equivalents were $19.824 million, current assets $22.687 million, current liabilities $3.994 million, and working capital $18.693 million. Total liabilities were $4.106 million; the balance sheet reports no debt balance. Accumulated deficit was $345.710 million. Cash used in operating activities in the first half was $3.942 million, investing activities used $0.031 million, and financing activities used $0.101 million, primarily for preferred dividends. Cash declined $4.086 million from year-end 2017. No revenue-based margin is meaningful because revenue was zero.
Material Changes Versus Prior Comparable Period
- First-half operating loss narrowed by $0.555 million and net loss by $0.541 million year over year, despite zero revenue.
- First-half R&D expense decreased $0.554 million. CYC065/transcriptional regulation spending rose $0.600 million to $1.106 million, while sapacitabine spending fell $1.170 million to $0.482 million, mainly due to lower SEAMLESS Phase 3 trial costs.
- First-half G&A expense was essentially unchanged at $2.647 million. Other income fell to $0.742 million from $0.866 million, primarily reflecting lower royalty-related income; interest income rose to $0.153 million.
- Cash used in first-half operations was $3.942 million versus $4.011 million a year earlier. Financing changed from $0.962 million provided in first-half 2017 to $0.101 million used in 2018; the earlier period included net common-stock issuance proceeds.
- Basic weighted-average shares were 11,997,447 in first-half 2018 versus 4,353,333 in first-half 2017, reflecting the prior-year share issuance. The lower loss per share should be viewed in that context.
Outlook, Commentary, and Risks
- Management said June 30 cash was expected to fund operating expenses and capital expenditures through the first quarter of 2020, and concluded there was no substantial doubt about going concern for at least one year from issuance. Funding beyond that period depends on raising additional capital.
- Management expects 2018 R&D expense to increase from 2017 as CYC065 development advances; G&A is expected to remain relatively flat. SEAMLESS spending and any potential regulatory submissions depend on discussions with European and U.S. regulators.
- The company completed stratified and exploratory subgroup analyses of SEAMLESS and said they identified a population that may benefit. It plans to discuss the data with regulators; no approval or filing outcome is assured.
- Management stated it lacks funds to complete development and commercialization of its candidates. If additional financing is unavailable on acceptable terms, it may reduce, delay, partner, or discontinue programs, or limit operations.
- Clinical, regulatory, financing, and commercialization outcomes remain uncertain. The company also cited foreign-exchange exposure, unpredictable royalty receipts under the ThermoFisher-related agreement, and compliance risks under international trade and data-protection laws, including the GDPR.
- A $0.066 million royalty receivable was recognized as other income in Q2 2018. A $0.150 million advance milestone payment under the ManRos agreement remained a contract liability; no revenue was recognized in the quarter or half-year. The filing says adoption of ASC 606 had no material financial-statement impact.
- A quarterly $0.15-per-share dividend on preferred stock was declared May 31, 2018 and paid August 1, 2018. The 6% convertible exchangeable preferred stock carries a $4.007 million aggregate liquidation preference and cumulative dividends.
Important Facts to Verify
- Confirm issuer identity: the supplied metadata names Bio Green Med Solution, Inc., but the filing identifies Cyclacel Pharmaceuticals, Inc.
- Verify the cash runway assumptions and the timing and availability of future financing; management’s stated runway extends only through Q1 2020.
- Track regulatory discussions and any decisions regarding SEAMLESS data, potential submissions, and continued trial spending.
- Assess clinical progress and cash requirements for CYC065 and the sapacitabine/seliciclib program against the company’s stated financing needs.
- Review potential dilution: 7,490,500 warrants were outstanding at a $2.00 exercise price, alongside preferred-stock conversion rights and equity awards.